Marshall Wace
SCLN

Marshall Wace’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Marshall Wace’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-31,731
Closed -$343K – 948
2016
Q4 		$343K Sell
31,731
-137,706
-81% -$1.38M ﹤0.01% 875
2016
Q3 		$1.74M Buy
+169,437
New +$1.85M 0.01% 626
2015
Q3 		– Sell
-11,991
Closed -$118K – 1158
2015
Q2 		$118K Buy
+11,991
New +$109K ﹤0.01% 846

Other funds holding SCLN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Marshall Wace's SCLN Position: Q1 2017 in Review

Marshall Wace sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q1 2017, closing a stake of 31,731 shares — an estimated $343K sold.

Marshall Wace first reported a position in SCLN in Q2 2015 and held it in 3 quarters. The position peaked at $1.74M in Q3 2016. 136 funds tracked by Wall St. Rank hold SCLN as of Q1 2017.

  • Marshall Wace reported no remaining Sciclone Pharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
  • Marshall Wace sold 31,731 Sciclone Pharmaceuticals Inc shares in Q1 2017, an estimated $343K.
  • Marshall Wace first reported a position in Sciclone Pharmaceuticals Inc in Q2 2015 and held it in 3 quarters.
  • Marshall Wace's Sciclone Pharmaceuticals Inc position peaked at $1.74M in Q3 2016.
  • 136 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q1 2017.

Based on Marshall Wace's 13F filing for Q1 2017, filed 12 May 2017.